Stoke Therapeutics (NASDAQ:STOK) General Counsel Jonathan Allan Sells 1,457 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Jonathan Allan sold 1,457 shares of the stock in a transaction on Tuesday, June 16th. The stock was sold at an average price of $29.95, for a total value of $43,637.15. Following the completion of the sale, the general counsel owned 18,086 shares of the company’s stock, valued at $541,675.70. The trade was a 7.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stoke Therapeutics Stock Up 2.4%

NASDAQ:STOK opened at $31.00 on Friday. The business’s 50-day simple moving average is $32.01 and its two-hundred day simple moving average is $32.35. Stoke Therapeutics, Inc. has a 52 week low of $11.17 and a 52 week high of $40.22. The stock has a market cap of $1.93 billion, a PE ratio of -11.03 and a beta of 1.17.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.79) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.01. The firm had revenue of $6.23 million during the quarter, compared to analyst estimates of $6.48 million. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%. Sell-side analysts anticipate that Stoke Therapeutics, Inc. will post -3.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in STOK. RTW Investments LP raised its position in shares of Stoke Therapeutics by 8.3% during the 4th quarter. RTW Investments LP now owns 5,546,856 shares of the company’s stock valued at $176,057,000 after buying an additional 423,331 shares in the last quarter. Redmile Group LLC grew its position in Stoke Therapeutics by 3.2% in the first quarter. Redmile Group LLC now owns 4,164,120 shares of the company’s stock worth $135,584,000 after acquiring an additional 130,050 shares in the last quarter. Morgan Stanley grew its position in Stoke Therapeutics by 0.3% in the fourth quarter. Morgan Stanley now owns 3,546,158 shares of the company’s stock worth $112,555,000 after acquiring an additional 9,108 shares in the last quarter. Vanguard Group Inc. increased its stake in Stoke Therapeutics by 7.4% during the third quarter. Vanguard Group Inc. now owns 3,163,874 shares of the company’s stock worth $74,351,000 after acquiring an additional 217,616 shares during the last quarter. Finally, State Street Corp increased its stake in Stoke Therapeutics by 75.2% during the fourth quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after acquiring an additional 1,072,176 shares during the last quarter.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Needham & Company LLC lifted their price objective on shares of Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Wall Street Zen cut shares of Stoke Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Weiss Ratings cut shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. Wolfe Research initiated coverage on shares of Stoke Therapeutics in a research note on Monday, February 23rd. They issued an “outperform” rating and a $40.00 price target on the stock. Finally, Canaccord Genuity Group increased their price objective on shares of Stoke Therapeutics from $36.00 to $60.00 and gave the company a “buy” rating in a report on Friday, March 20th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $41.83.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.